About PLx Pharma (NASDAQ:PLXP)
PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. Its lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. The company's product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development. The company was founded in 2002 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PLXP
CUSIPN/A
Phone713-842-1249
Debt
Debt-to-Equity Ratio1.51%
Current Ratio14.19%
Quick Ratio14.06%
Price-To-Earnings
Trailing P/E Ratio-2.10
Forward P/E Ratio-2.52
P/E GrowthN/A
Sales & Book Value
Annual Sales$780,000.00
Price / Sales45.89
Cash FlowN/A
Price / CashN/A
Book Value$0.53 per share
Price / Book7.74
Profitability
EPS (Most Recent Fiscal Year)($1.95)
Net Income$-15,340,000.00
Net MarginsN/A
Return on Equity-113.26%
Return on Assets-46.16%
Miscellaneous
Employees14
Outstanding Shares8,730,000
PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions
What is PLx Pharma's stock symbol?
PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."
How were PLx Pharma's earnings last quarter?
PLx Pharma (NASDAQ:PLXP) released its quarterly earnings results on Friday, March, 23rd. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.07. The biotechnology company had revenue of $0.34 million for the quarter. View PLx Pharma's Earnings History.
What price target have analysts set for PLXP?
3 brokerages have issued 1 year price targets for PLx Pharma's stock. Their forecasts range from $12.00 to $14.00. On average, they anticipate PLx Pharma's share price to reach $13.00 in the next twelve months. View Analyst Ratings for PLx Pharma.
Who are some of PLx Pharma's key competitors?
Some companies that are related to PLx Pharma include Acer Therapeutics (ACER), BioXcel Therapeutics (BTAI), Aldeyra Therapeutics (ALDX), Zynerba Pharmaceuticals (ZYNE), Bellerophon Therapeutics (BLPH), Aeglea Bio Therapeutics (AGLE), Sierra Oncology (SRRA), Cerecor (CERC), Galectin Therapeutics (GALT), Evofem Biosciences (EVFM), BioDelivery Sciences International (BDSI), Checkpoint Therapeutics (CKPT), Affimed (AFMD), Adamis Pharmaceuticals (ADMP) and AcelRx Pharmaceuticals (ACRX).
Who are PLx Pharma's key executives?
PLx Pharma's management team includes the folowing people:
- Mr. Michael J. Valentino, Exec. Chairman (Age 64)
- Ms. Natasha Giordano, Chief Exec. Officer, Pres and Director (Age 58)
- Mr. Gary L. Mossman, Sr. Advisor (Age 77)
- Mr. Ronald R. Zimmerman, Founder and Sr. Advisor (Age 65)
- Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 50)
When did PLx Pharma IPO?
(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.
Has PLx Pharma been receiving favorable news coverage?
News headlines about PLXP stock have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. PLx Pharma earned a news impact score of 0.21 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.41 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of PLx Pharma?
Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PLx Pharma's stock price today?
One share of PLXP stock can currently be purchased for approximately $4.10.
How big of a company is PLx Pharma?
PLx Pharma has a market capitalization of $37.52 million and generates $780,000.00 in revenue each year. The biotechnology company earns $-15,340,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. PLx Pharma employs 14 workers across the globe.
How can I contact PLx Pharma?
PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]
MarketBeat Community Rating for PLx Pharma (PLXP)
MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
PLx Pharma (NASDAQ:PLXP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for PLx Pharma in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 217.07%. The high price target for PLXP is $14.00 and the low price target for PLXP is $12.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.00 | $13.00 | $13.00 | $12.00 |
| Price Target Upside: | 217.07% upside | 152.43% upside | 113.11% upside | 93.55% upside |
PLx Pharma (NASDAQ:PLXP) Consensus Price Target History
PLx Pharma (NASDAQ:PLXP) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
PLx Pharma (NASDAQ:PLXP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
PLx Pharma (NASDAQ PLXP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 47.70%
Institutional Ownership Percentage: 24.60%
PLx Pharma (NASDAQ PLXP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/14/2017 | David Emerson Jorden | CFO | Buy | 32,727 | $6.88 | $225,161.76 | 151,913 |  |
| 6/14/2017 | Gary L Mossman | COO | Buy | 7,273 | $6.88 | $50,038.24 | 78,255 | |
| 6/14/2017 | Michael J Valentino | Insider | Buy | 29,091 | $6.88 | $200,146.08 | 122,386 | |
| 5/21/2014 | Jack H Dean | Director | Buy | 3,000 | $9.00 | $27,000.00 | | |
| 3/18/2014 | David Garrett | VP | Buy | 2,083 | $12.00 | $24,996.00 | | |
| 3/18/2014 | Thomas L Harrison | Director | Buy | 2,000 | $12.00 | $24,000.00 | | |
(Data available from 1/1/2013 forward)
PLx Pharma (NASDAQ PLXP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | PLx Pharma (PLXP) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 8 at 10:35 AM |
| PLx Pharma Inc (PLXP) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 9:08 AM |
| PLx Pharma (PLXP) Cut to Neutral at Janney Montgomery Scott
www.americanbankingnews.com - March 26 at 9:04 AM |
| PLx Pharma (PLXP) Releases Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - March 25 at 5:35 PM |
 | PLx Pharma's (PLXP) CEO Natasha Giordano on Q4 2017 Results - Earnings Call Transcript
www.msn.com - March 23 at 5:41 PM |
 | PLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 23 at 8:19 AM |
| PLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call
finance.yahoo.com - March 15 at 6:11 PM |
| PLx Pharma Inc (PLXP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 2:13 PM |
| PLx Pharma Inc (PLXP) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 11:48 AM |
| Contrasting PLx Pharma (PLXP) & The Competition
www.americanbankingnews.com - January 23 at 3:24 AM |
| PLx Pharma (PLXP) Now Covered by Janney Montgomery Scott
www.americanbankingnews.com - January 20 at 7:38 PM |
 | Analyst Actions: PLx Pharma Initiated by Janney With Buy Rating, $14/Share Price Target
www.nasdaq.com - January 19 at 5:12 PM |
| PLx Pharma Inc (PLXP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 10:32 AM |
| Critical Review: PLx Pharma (PLXP) vs. Its Competitors
www.americanbankingnews.com - January 14 at 11:06 PM |
| Brokerages Expect PLx Pharma Inc (PLXP) to Announce ($0.51) EPS
www.americanbankingnews.com - January 6 at 3:20 AM |
| PLx Pharma (PLXP) and Its Peers Head-To-Head Analysis
www.americanbankingnews.com - December 29 at 3:28 AM |
| PLx Pharma Inc (PLXP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 17 at 1:50 AM |
| Comparing Ascendis Pharma A/S (ASND) & PLx Pharma (PLXP)
www.americanbankingnews.com - December 16 at 1:32 PM |
| PLx Pharma Inc (PLXP) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 11 at 1:36 PM |
| PLx Pharma (PLXP) Lifted to Sell at ValuEngine
www.americanbankingnews.com - December 4 at 9:38 PM |
| Brokerages Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP)
www.americanbankingnews.com - November 26 at 3:40 PM |
| Is PLx Pharma Inc’s (PLXP) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 22 at 6:43 AM |
| Dipexium Pharmaceuticals, Inc. (PLXP) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 18 at 8:18 PM |
| Zacks: Analysts Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP)
www.americanbankingnews.com - November 13 at 3:03 PM |
| PLx Pharma Inc. Reports Third Quarter 2017 Results
finance.yahoo.com - November 12 at 11:44 AM |
| PLx Pharma reports 3Q loss
finance.yahoo.com - November 12 at 11:44 AM |
| PLx Pharma, Inc. to Host Earnings Call
finance.yahoo.com - November 12 at 11:44 AM |
| PLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference Call
finance.yahoo.com - November 4 at 8:55 AM |
| Dipexium Pharmaceuticals, Inc. (PLXP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 15 at 12:16 PM |
| Dipexium Pharmaceuticals, Inc. (PLXP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 14 at 2:18 AM |
| Dipexium Pharmaceuticals (PLXP) & ZIOPHARM Oncology (ZIOP) Head-To-Head Comparison
www.americanbankingnews.com - October 2 at 8:14 PM |
| PLx Pharma Present at the Sidoti & Company Fall 2017 Conference
finance.yahoo.com - September 19 at 6:33 AM |
| PLx Pharma Retains Dr. Efthymios N. Deliargyris as Chief Medical Advisor
finance.yahoo.com - September 13 at 7:49 AM |
| Head-To-Head Survey: Dipexium Pharmaceuticals (PLXP) and Kindred Biosciences (KIN)
www.americanbankingnews.com - August 21 at 4:24 PM |
| PLx Pharma Inc. Reports Second Quarter 2017 Results
finance.yahoo.com - August 11 at 7:36 AM |
| PLx Pharma reports 2Q loss
finance.yahoo.com - August 11 at 7:36 AM |
| Dipexium Pharmaceuticals, Inc. (PLXP) Rating Increased to Outperform at Redburn Partners
www.americanbankingnews.com - August 1 at 3:56 PM |
| Dipexium Pharmaceuticals, Inc. (PLXP) Upgraded by Raymond James Financial, Inc. to "Outperform"
www.americanbankingnews.com - July 31 at 5:30 PM |
| UBS AG Upgrades Dipexium Pharmaceuticals, Inc. (PLXP) to "Outperform"
www.americanbankingnews.com - July 31 at 4:28 PM |
| Dipexium Pharmaceuticals, Inc. (PLXP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 8:22 PM |
 | Money Makers: Houston pharma co., construction company file multimillion-dollar raises
www.bizjournals.com - July 8 at 11:46 PM |
 | Protalix BioTherapeutics' (PLX) CEO Moshe Manor on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 8:18 AM |
 | BRIEF-Rita O'Connor appointed CFO of PLx Pharma
www.reuters.com - May 2 at 5:04 PM |
 | PLx Pharma Inc. (PLXP) Names Rita O’Connor as CFO
www.streetinsider.com - May 2 at 5:04 PM |
PLx Pharma (NASDAQ:PLXP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
PLx Pharma (NASDAQ:PLXP) Income Statement, Balance Sheet and Cash Flow Statement
PLx Pharma (NASDAQ PLXP) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
